David Lally to Wet Macular Degeneration
This is a "connection" page, showing publications David Lally has written about Wet Macular Degeneration.
Connection Strength
2.269
-
Choi H, Corradetti G, Lindenberg S, Karamat AN, Oncel D, Liu H, Gnanaraj R, Fasih-Ahmad S, Marion KM, Baker KL, Gulati S, Foster B, Lam A, Sadda SR, Lally DR. Incomplete RPE and Outer Retinal Atrophy (iRORA) Development in Eyes With Fellow-eye Neovascular Age-related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2025 May; 56(5):274-279.
Score: 0.932
-
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.
Score: 0.773
-
Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2012 May; 23(3):182-8.
Score: 0.385
-
Enr?quez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, Enr?quez JR, Eichenbaum DA. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021 Apr 01; 139(4):441-448.
Score: 0.179